약학회지

ISSN 0377-9556 (PRINT)
ISSN 2383-9457 (ONLINE)

Table. 7.

Table. 7.

Sensitivity analyses of the causal inference approach of the association of statin use with cirrhosis and hepatocellular carcinoma

Outcome Methods of causal inference Propensitiy score match IPW analysis SuperlearningTMLE



§ATE 95%CI ATE 95%CI ATE 95%CI
Cirrhosis Statin use -0.022** -0.028 ~ -0.015 -0.023** -0.028 ~ -0.017 -0.028** -0.0334 ~ -0.023
Atorvastatin -0.025** -0.031 ~ -0.019 -0.023** -0.028 ~ -0.018 -0.027** -0.032 ~ -0.021

Hepatocellular carcinoma Statin use -0.014** -0.019 ~ -0.009 -0.015** -0.019 ~ -0.011 -0.017** -0.021 ~ -0.013
Atorvastatin -0.014** -0.020 ~ -0.009 -0.015** -0.019 ~ -0.012 -0.016** -0.020 ~ -0.012

§ Average treatment effect (ATE) from causal inference of propensity score match analysis, with adjustment for dyslipidemia, cardiovascular disease, high blood pressure, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

Average treatment effect (ATE) from causal inference of inverse probability weighting anaylsis, with adjustment for dyslipidemia, cardiovascular disease, high blood pressure, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

Average treatment effect (ATE) from causal inference of superlearning targeted maximum likelihood estimation, with adjustment for dyslipidemia, cardiovascular disease, high blood pressure, cerebrovascular disease, diabetes mellitus, antihypertensive medication, antidiabetic medication, and lipid-lowering agents (except statin).

* p<0.05, ** p<0.01

Yakhak Hoeji 2024;68:44-55 https://doi.org/10.17480/psk.2024.68.1.44
© 2024 Yakhak Hoeji